Iowa’s Senate revived a narrower psilocybin therapy proposal for PTSD patients, setting up a new fight over science, safeguards and state action before federal approval.

A Canadian ranking found alcohol and tobacco cause more overall harm than cannabis, raising hard questions about drug policy and patient access.

Massachusetts Considers a Cultivation Freeze as Prices Sink years in the making

Missouri’s new cannabis guidance softens a hard “no” on medical patients buying as adult-use consumers yet leaves regulators, patients and dispensaries with unresolved questions about limits and enforcement.

Well-funded campaigns in Maine and Massachusetts aim to dismantle adult-use cannabis markets, threatening patients, revenue and voter-approved reform.

Maine officials have cleared a 2026 ballot campaign that would dismantle the state’s adult-use marijuana market while tightening rules for medical cannabis.

Trump’s Schedule III move ends tax penalties but invites FDA oversight, leaving patients and equity growers vulnerable. Critics call it a bailout for Big Pharma, not real reform.

What Trump marijuana rescheduling and emerging Medicare CBD policies could mean for federal law, the cannabis industry and seniors who depend on government health coverage.

UK‑based Ananda Pharma is advancing MRX‑1 to treat endometriosis‑associated pain, signalling a shift toward regulated cannabinoid medicines backed by clinical trials.

Legal cannabis in Africa is booming, but traditional rural growers face exclusion from a system dominated by capital, regulation, and global investors.

A cannabis-derived drug, DKJ127, eased chronic back pain in a large trial, offering hope as a safer alternative to opioids.